Yes, dry macular degeneration can turn into wet macular degeneration, and in fact, wet AMD always begins as the dry form first. The conversion isn’t inevitable, though. Most people with dry AMD will never develop the wet type, but the risk increases with the severity of your disease, ranging from about 2% for early-stage dry AMD to roughly 13 to 18% over three years for higher-risk eyes.
How Often Dry AMD Becomes Wet
The likelihood of conversion depends heavily on how advanced your dry AMD is. A large analysis from the American Academy of Ophthalmology’s registry found that overall conversion rates were 2.0% for early-stage, 6.1% for intermediate-stage, and 6.7% for advanced dry AMD. Other estimates put the one-year risk between 1% and 4.7%, climbing to 13 to 18% at three years. These numbers mean the vast majority of people with early dry AMD will stay in the dry form, but anyone with intermediate or advanced disease needs closer monitoring.
For context, dry AMD accounts for the large majority of all macular degeneration cases. Wet AMD is less common but far more destructive to vision when it does develop, because it can cause rapid, severe central vision loss within weeks or months if untreated.
What Happens Biologically During Conversion
In dry AMD, the retina gradually breaks down over years. Small deposits called drusen accumulate beneath the retina, and the light-sensitive cells slowly deteriorate. The shift to wet AMD happens when the retina, under stress from this ongoing damage, starts producing too much of a growth signal called VEGF. This chemical triggers new, abnormal blood vessels to sprout from the layer beneath the retina and grow upward into it.
These new vessels are fragile and leaky. They ooze fluid and blood into the retina, which distorts and damages the delicate tissue responsible for sharp central vision. This is why wet AMD causes much faster vision loss than dry AMD, where the decline is typically gradual over years or decades.
Risk Factors That Increase Your Chances
Not everyone with dry AMD faces equal risk. Several specific features visible on eye imaging predict a higher chance of conversion to wet AMD.
Drusen size and location matter significantly. Large drusen are more strongly associated with progression to late-stage disease than small or medium ones. Drusen located near the fovea (the very center of your retina, responsible for your sharpest vision) carry a higher risk than drusen further out. The total number of drusen and the area they cover also increase risk.
Pigmentary changes in the retina are another major warning sign. When pigment abnormalities appear alongside drusen, the risk of developing late AMD increases dramatically. On imaging, small bright spots called hyperreflective foci, which correspond to these pigment changes, are particularly concerning. Nearly half of eyes with these spots progress to wet AMD within two years.
A special type of deposit called reticular pseudodrusen also signals elevated risk. These are especially common in the fellow eye of someone who already has wet AMD in one eye, and they carry a progression rate to wet AMD of about 30% over two years, regardless of other features present. If you already have wet AMD in one eye, your other eye is at substantially higher risk of converting.
Beyond what’s visible in the eye, demographic factors like older age, smoking history, and genetic predisposition play a role, particularly in predicting progression at earlier stages of the disease.
Warning Signs of Conversion
The shift from dry to wet AMD often announces itself with sudden visual changes that feel distinctly different from the slow, gradual blurring of dry AMD. The hallmark symptom is distortion: straight lines, like door frames or text on a page, appear bent or wavy. You might also notice a new blurry spot or blind spot in the center of your vision, increased difficulty reading or recognizing faces, or a sudden need for brighter light during close-up tasks.
These symptoms typically appear quickly and worsen fast. If you’ve been living with the slow progression of dry AMD and suddenly notice any of these changes, that’s a signal to contact your eye specialist promptly. Early treatment for wet AMD can preserve significantly more vision than delayed treatment.
Monitoring at Home With an Amsler Grid
An Amsler grid is a simple printed chart with a grid of straight lines and a dot in the center. It’s one of the most practical tools for catching the transition from dry to wet AMD early. A healthy eye will see all the lines as straight. An eye developing wet AMD will often see some lines as wavy, curved, or partially blocked by a gray, white, or black spot.
To use it, hold the grid at reading distance with your reading glasses on. Cover one eye completely and focus on the center dot with the other. Look for any lines that appear wavy, dim, fuzzy, or missing. Then switch eyes and repeat. Testing one eye at a time is critical because a healthy eye can compensate for problems in the other, masking early changes you need to catch.
Check once a week. If you notice new waviness, a growing area of distortion, or a new blind spot, contact your retina specialist right away. The grid is a useful early-warning tool, but it doesn’t replace regular eye exams with imaging that can detect changes before you notice symptoms.
What You Can Do to Lower the Risk
The most well-studied intervention is the AREDS2 supplement formula, a specific combination of antioxidant vitamins, zinc, copper, lutein, and zeaxanthin developed through clinical trials funded by the National Eye Institute. For people with intermediate AMD or advanced AMD in one eye, taking these supplements reduces the risk of progressing to advanced disease (including wet AMD) by about 25% and lowers the risk of central vision loss by 19%.
These supplements don’t prevent AMD from developing in the first place, and they’re not recommended for people with only early-stage disease. They’re specifically beneficial for people already at intermediate or higher risk. The current AREDS2 formula replaced the original version’s beta-carotene with lutein and zeaxanthin, which provided a small additional benefit and eliminated a lung cancer risk associated with beta-carotene in smokers.
Beyond supplements, the general risk-reduction strategies that apply to AMD overall remain relevant: not smoking (or quitting if you do), maintaining cardiovascular health, eating a diet rich in leafy greens and fish, and protecting your eyes from prolonged UV exposure. None of these guarantee prevention, but they address modifiable factors linked to disease progression.
What Treatment Looks Like If Conversion Happens
If your dry AMD does convert to wet, the standard treatment involves injections of medication directly into the eye that block VEGF, the growth signal responsible for the abnormal blood vessels. These injections can stop the leaking vessels and, in many cases, improve vision that was recently lost. Treatment typically starts with injections every four to eight weeks, and many people continue them long-term on a schedule tailored to their response.
The injections sound intimidating, but the eye is numbed beforehand, and most people describe the sensation as pressure rather than pain. The key factor in outcomes is timing. People who begin treatment soon after conversion, before significant scarring occurs, tend to keep more of their vision. This is why regular monitoring, both at home and with your specialist, matters so much when you’re living with dry AMD.